Tisotumab vedotin clinical trials
Also written TIVDAK.
How each study uses tisotumab vedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tisotumab vedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 20 Sept 2021 · TIVDAK · BLA 761208 (FDA, Drugs@FDA)
- European Union
- 28 Mar 2025 · Tivdak · EMEA/H/C/005363 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 3 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 1
Seagen Inc. (5) · Seagen, a wholly owned subsidiary of Pfizer (3) · Zai Lab (Shanghai) Co., Ltd. (1) · Genmab (1) · GOG Foundation (1) · Pfizer (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Tisotumab vedotin is the comparator. A study of two new drugs counts under both.
- 1Sacituzumab tirumotecan · Merck Sharp & Dohme LLC · next primary completion Jun 2028
Studies
Open first, then newest update. How each study uses tisotumab vedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Tisotumab Vedotin in Squamous Cell Carcinoma of the VulvaNot yet recruitingPhase 2GOG FoundationNCT07672782Written as Tisotumab Vedotin
- Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical CancerRecruitingPhase 4PfizerNCT06952660Written as TIVDAK
- Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsActive, not recruitingPhase 2Seagen, a wholly owned subsidiary of PfizerNCT03485209Written as tisotumab vedotin
- Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical CancerTerminatedPhase 1/2Seagen, a wholly owned subsidiary of PfizerNCT03786081Written as Tisotumab Vedotin
- Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical CancerCompletedPhase 3Seagen, a wholly owned subsidiary of PfizerNCT04697628Written as tisotumab vedotin
- To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid MalignanciesCompletedPhase 1Zai Lab (Shanghai) Co., Ltd.NCT05866354Written as Tisotumab Vedotin
- A Trial of Tisotumab Vedotin in Cervical CancerCompletedPhase 2Seagen Inc.NCT03438396Written as tisotumab vedotin
- A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)CompletedPhase 2Seagen Inc.NCT03657043Written as tisotumab vedotin
- A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid MalignanciesCompletedPhase 1/2GenmabNCT03913741Written as tisotumab vedotin
- Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedPhase 1/2Seagen Inc.NCT02001623Written as Tisotumab Vedotin (HuMax-TF-ADC)
- Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.CompletedPhase 2Seagen Inc.NCT03245736Written as Tisotumab Vedotin
- Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedPhase 1/2Seagen Inc.NCT02552121Written as Tisotumab vedotin (HuMax-TF-ADC)
As the comparator · 1 — what is tested is compared with tisotumab vedotin
Codes
What other systems call tisotumab vedotin · ClinicalTrials.gg INT001329
- MeSH (NLM) C000707142tisotumab vedotinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) T41737F88ATISOTUMAB VEDOTINConfirmed FDA, NLM, Wikidata
- RxNorm 2571094One source FDA
- Wikidata Q108670929tisotumab vedotinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C113164Tisotumab VedotinOne source FDA
- DrugBank DB16732One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000707142 | tisotumab vedotin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | T41737F88A | TISOTUMAB VEDOTIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2571094 | — | One source FDA |
| Wikidata | Q108670929 | tisotumab vedotin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C113164 | Tisotumab Vedotin | One source FDA |
| DrugBank | DB16732 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.